New data presentations reinforce clinical value of Elekta’s Monaco radiotherapy treatment planning software
The latest version of Elekta’s Monaco® treatment planning software was recently highlighted in multiple presentations. The only treatment planning solution with gold-standard Monte Carlo accuracy and multicriteria optimization, Monaco supports radiotherapy techniques, including advanced 3D, intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and highly-complex stereotactic treatments. Monaco empowers users to attain accuracy without compromise for faster, more efficient treatment planning. Template sharing functionality complemented by Radiation Therapy Oncology Group (RTOG) and user-based integrated templates enable class solution planning and best practice sharing across departments, organizations, and professional communities.
“The latest version of Elekta’s Monaco software offers several enhancements to optimize patient workflow, including a significantly faster optimization time and template planning,” said Sotiri Stathakis, Ph.D., Associate Professor, Radiation Oncology and Radiology at University of Texas Health Science Center in San Antonio, Texas. “These data demonstrate that Monaco software supports highly accurate treatment planning, using best-in-class Monte Carlo dose calculations, in a range of clinical environments.”
Recent presentations presented during the 58th American Association of Physicists in Medicine Annual Meeting & Exhibition highlighting Monaco include:
- “Differences in Lung Sparing in Deep Inspiration Breath-Hold and Free Breathing Breast Plans Calculated in Pinnacle and Monaco”
This presentation described five patients undergoing deep inspiration breath-hold (DIBH) breast radiotherapy. Breath hold and free breathing plans doses were initially determined using the Phillips Pinnacle system and re-calculated with Monaco to determine if there were significant differences. Researchers reported equivalent dose reductions for both systems, with observed lung doses that were significantly higher when calculated using the Monte Carlo algorithm in Monaco. The authors state that Monte Carlo calculation can provide insight into dose in the actual dose in lung for both breath hold and free breathing breast cancer patients treated with radiation.
- “Monte Carlo Re-Evaluation of Volumetric-Modulated Arc Plans of Advanced Stage Nasopharyngeal Cancers Optimized with Convolution-Superposition Algorithm”
This study examined Monaco recalculation of 29 treatment plans for advanced-stage nasopharyngeal cancers (NPC). Results demonstrated that significant dosimetric differences in NPC treatment plans were observed between a convolution-superposition (CS) algorithm used in the Pinnacle system and the Monte Carlo calculations in Monaco software. Results indicated that PTV54-70Gy doses are higher and consistently predicted by Monte Carlo. The authors conclude that adjustments of the planning dose constraints to incorporate the physics differences from a conventional CS algorithm should be made when optimization is carried out directly with a Monte Carlo dose engine.
In this study, researchers evaluated 20 treatment plans that were generated using the iPlan system and calculated using the pencil beam algorithm. CT image sets along with the plan, doses and structures were exported to the Monaco treatment planning software (TPS) and the dose was recalculated using the same voxel resolution (a value on a regular grid in three-dimensional space) and monitor units. Benchmark data was also generated prior to patient calculations to assess accuracy of the two TPS against measurements using a micro ionization chamber in solid water. Authors observed good agreement for measurements in water and noted that dosing differences varied up to 9.6 percent, concluding that Monte Carlo is a superior dose calculation algorithm.
This study exported 14 patients’ files from the Pinnacle TPS to Monaco. All plans were recalculated within Monaco using a Monte-Carlo algorithm and prescription isodose volume to target volume ratio (PITV), R50 (the ratio of the volume irradiated to 50% of the prescribed dose to the volume of the planning treatment volume), conformity (a measurement of how well the dose was delivered to the target) and homogeneity indices were computed and used for SBRT plan evaluation. The mean PITV for Monaco increased 7% over Pinnacle, while the standard deviation increased from 0.047 to 0.076. The Homogeneity Index increased from 1.32 to 1.35. The Target Coverage decreased slightly from 0.98 to 0.97, with standard deviations for Homogeneity Index and Target coverage varying insignificantly by less than 0.2%. Researchers concluded that the increase PITV shows that the prescription dose volume increased in the treatment plans calculated by Monaco. The value of Monaco’s Monte Carlo calculation accuracy to stereotactic (small) field dosimetry was demonstrated by the authors. It was shown that dose inaccuracy greater than 5% (the level of clinical significance) is possible when non-Monte Carlo calculations are used, implying that Monte Carlo is valuable to patients being treated with small stereotactic fields.
- “Validation of Monte-Carlo Beam Model for a Range of Small Fields in Heterogeneous Medium - A Measurement Based Study”
This study was designed to validate the Monaco Monte Carlo beam model by studying effects on three different types of phantoms selected to resemble the densities of lung, soft tissue and bone. Researchers concluded that the accuracy of dose calculation for the small fields in Monaco Monte Carlo algorithm was validated in the three different materials, and found that the results were consistent with measurement data.
“Elekta has a long-standing commitment to developing and implementing software systems that support improved treatment efficiencies for patients and clinicians,” said Dee Mathieson, Senior Vice President, Treatment Management Portfolio, Elekta. “These recent data underscore Monaco’s advanced performance and precision in radiotherapy treatment planning, further validating the importance of accurate dose calculation in complex stereotactic radiosurgery procedures.”
For more information on Monaco 5.11, visit www.elekta.com/monaco.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: firstname.lastname@example.org
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: email@example.com
Time zone: EST: Eastern Standard Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com Twitter: @Elekta.